2022
Al-Bazz, D. Y., Nelson, A. J., Burgess, J., Petropoulos, I. N., Nizza, J., Marshall, A., . . . Alam, U. (2022). Is Nerve Electrophysiology a Robust Primary Endpoint in Clinical Trials of Treatments for Diabetic Peripheral Neuropathy?. DIAGNOSTICS, 12(3). doi:10.3390/diagnostics12030731DOI: 10.3390/diagnostics12030731
2021
Brown, E., Hydes, T., Hamid, A., & Cuthbertson, D. J. (2021). Emerging and Established Therapeutic Approaches for Nonalcoholic Fatty Liver Disease. CLINICAL THERAPEUTICS, 43(9), 1476-1504. doi:10.1016/j.clinthera.2021.07.013DOI: 10.1016/j.clinthera.2021.07.013
Hydes, T., Brown, E., Hamid, A., Bateman, A. C., & Cuthbertson, D. J. (2021). Current and Emerging Biomarkers and Imaging Modalities for Nonalcoholic Fatty Liver Disease: Clinical and Research Applications. Clinical Therapeutics. doi:10.1016/j.clinthera.2021.07.012DOI: 10.1016/j.clinthera.2021.07.012
Brown, E., Wilton, M. M., Sprung, V. S., Harrold, J. A., Halford, J. C. G., Stancak, A., . . . Cuthbertson, D. J. (2021). A randomised, controlled, double blind study to assess mechanistic effects of combination therapy of dapagliflozin with exenatide QW versus dapagliflozin alone in obese patients with type 2 diabetes mellitus (RESILIENT): study protocol. BMJ open, 11(7), e045663. doi:10.1136/bmjopen-2020-045663DOI: 10.1136/bmjopen-2020-045663
Brown, E., Heerspink, H. J. L., Cuthbertson, D. J., & Wilding, J. P. H. (2021). SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications. LANCET, 398(10296), 262-276. doi:10.1016/S0140-6736(21)00536-5DOI: 10.1016/S0140-6736(21)00536-5
Kirthi, V., Perumbalath, A., Brown, E., Nevitt, S., Petropoulos, I. N., Burgess, J., . . . Alam, U. (2021). Prevalence of peripheral neuropathy in pre-diabetes: a systematic review. BMJ OPEN DIABETES RESEARCH & CARE, 9(1). doi:10.1136/bmjdrc-2020-002040DOI: 10.1136/bmjdrc-2020-002040
Eleftheriadou, A., Williams, S., Nevitt, S., Brown, E., Roylance, R., Wilding, J. P. H., . . . Alam, U. (2021). The prevalence of cardiac autonomic neuropathy in prediabetes: a systematic review. DIABETOLOGIA, 64(2), 288-303. doi:10.1007/s00125-020-05316-zDOI: 10.1007/s00125-020-05316-z
Cuthbertson, D. J., Koskinen, J., Brown, E., Magnussen, C. G., Hutri-Kahonen, N., Sabin, M., . . . Juonala, M. (2021). Fatty liver index predicts incident risk of prediabetes, type 2 diabetes and non-alcoholic fatty liver disease (NAFLD). ANNALS OF MEDICINE, 53(1), 1256-1264. doi:10.1080/07853890.2021.1956685DOI: 10.1080/07853890.2021.1956685
Brown, E., Wilding, J. P. H., Alam, U., Barber, T. M., Karalliedde, J., & Cuthbertson, D. J. (2021). The expanding role of SGLT2 inhibitors beyond glucose-lowering to cardiorenal protection. ANNALS OF MEDICINE, 53(1), 2072-2089. doi:10.1080/07853890.2020.1841281DOI: 10.1080/07853890.2020.1841281
2020
Hydes, T. J., Summers, N., Brown, E., Alam, U., Thomaides-Brears, H., Wilding, J. P. H., & Cuthbertson, D. J. (2020). Mechanisms, screening modalities and treatment options for individuals with non‐alcoholic fatty liver disease and type 2 diabetes. Diabetic Medicine. doi:10.1111/dme.14356DOI: 10.1111/dme.14356
Multiparametric magnetic resonance imaging of the liver demonstrates the prevalence of steatohepatitis in patients with type 2 diabetes (Conference Paper)
Brown, E., Waddell, T., Mouchti, S., Roca-Fernandez, A., Thomaides-Brears, H., Wilton, M., . . . Banerjee, R. (2020). Multiparametric magnetic resonance imaging of the liver demonstrates the prevalence of steatohepatitis in patients with type 2 diabetes. In DIABETOLOGIA Vol. 63 (pp. S420-S421). Retrieved from https://www.webofscience.com/
2019
Brown, E., Wilding, J. P. H., Barber, T. M., Alam, U., & Cuthbertson, D. J. (2019). Weight loss variability with SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes mellitus and obesity: Mechanistic possibilities. OBESITY REVIEWS, 20(6), 816-828. doi:10.1111/obr.12841DOI: 10.1111/obr.12841
Cuthbertson, D. J., Brown, E., Koskinen, J., Magnussen, C. G., Hutri-Kahonen, N., Sabin, M., . . . Juonala, M. (2019). Longitudinal analysis of risk of non-alcoholic fatty liver disease in adulthood. LIVER INTERNATIONAL, 39(6), 1147-1154. doi:10.1111/liv.13993DOI: 10.1111/liv.13993
A review of the mechanism of action, metabolic profile and haemodynamic effects of sodium-glucose co-transporter-2 inhibitors (Journal article)
Brown, E., Rajeev, S. P., Cuthbertson, D. J., & Wilding, J. P. H. (2019). A review of the mechanism of action, metabolic profile and haemodynamic effects of sodium-glucose co-transporter-2 inhibitors. DIABETES OBESITY & METABOLISM, 21, 9-18. doi:10.1111/dom.13650DOI: 10.1111/dom.13650
Severe insulin resistance and childhood obesity: A familial disorder in two siblings (Conference Paper)
Lim, J. Z., Mon, A., Brown, E., Alam, U., & Wilding, J. P. (2019). Severe insulin resistance and childhood obesity: A familial disorder in two siblings. In DIABETIC MEDICINE Vol. 36 (pp. 140). Retrieved from https://www.webofscience.com/
2018
Changes in Energy Balance during Dapagliflozin Therapy in Type 2 Diabetes-The Energize Study (Conference Paper)
Rajeev, S. P., Roberts, C. A., Cuthbertson, D. J., Sprung, V. S., Brown, E., Halford, J. C. J., . . . Wilding, J. P. (2018). Changes in Energy Balance during Dapagliflozin Therapy in Type 2 Diabetes-The Energize Study. In DIABETES Vol. 67. doi:10.2337/db18-1163-PDOI: 10.2337/db18-1163-P
Brown, E., Watkin, D., Evans, J., Yip, V., & Cuthbertson, D. J. (2018). Multidisciplinary management of refractory insulinomas. CLINICAL ENDOCRINOLOGY, 88(5), 615-624. doi:10.1111/cen.13528DOI: 10.1111/cen.13528
Brown, E., Cuthbertson, D. J., & Wilding, J. P. (2018). Newer GLP-1 receptor agonists and obesity-diabetes. PEPTIDES, 100, 61-67. doi:10.1016/j.peptides.2017.12.009DOI: 10.1016/j.peptides.2017.12.009
2016
Are cholesterol levels being checked and managed appropriately in primary UK care for Type 2 diabetes? (Conference Paper)
Livingston, M., Robinson, J. C., Brown, C. E., Narayanan, R. P., Holland, D., Fryer, A. A., & Heald, A. H. (2016). Are cholesterol levels being checked and managed appropriately in primary UK care for Type 2 diabetes?. In DIABETIC MEDICINE Vol. 33 (pp. 84). Retrieved from https://www.webofscience.com/
2012
Adrenocortical carcinoma: an unusual genetic cause! (Journal article)
Brown, E., Hardy, R., Weber, A., Daousi, C., Wieshmann, H., Sheard, J., & Cuthbertson, D. J. (2012). Adrenocortical carcinoma: an unusual genetic cause!. CLINICAL ENDOCRINOLOGY, 77(5), 787-+. doi:10.1111/j.1365-2265.2012.04377.xDOI: 10.1111/j.1365-2265.2012.04377.x